The FDA recently approved Treximet for use in patients aged 12 years and older for the acute treatment of migraine with or without aura, according to the drug’s manufacturer.A combination of sumatriptan and naproxen sodium, Treximet (Pernix Therapeutics) is the first approved combination prescription medicine for the treatment of acute migraine attacks in pediatric patients to contain sumatriptan. It is expected to provide more effective, sustained control of the pain and associated symptoms of migraine than either medicine alone.
No comments:
Post a Comment